SlideShare une entreprise Scribd logo
1  sur  8
Télécharger pour lire hors ligne
Public Knowledge,
Perceptions, and
Intentions for Biologic
and Biosimilar Medicines
Info@ISRreports.com 	 	
	
©2013 Industry Standard Research www.ISRreports.com
PREVIEW
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 2
act with confidence
Report Overview
T
his research was designed to provide pharmaceutical sales, marketing, and brand management with
data to better understand how US patients will make decisions regarding their purchase and use of
biosimilar medications.
Major Sections:
1. Executive Summary
2. Medication Decision-making
Explores high-level prescribing activities and reveals patients’ predispositions when making prescription decisions.
For example, ISR reveals patients’ likelihood to switch to a generic medication against doctor’s orders, how often
they consult a pharmacist regarding drug decisions, and how often they request a generic alternative.
3. Biologic and Biosimilar Prescription Choice Models
ISR analyzes the level of importance patients place on several prescription medication attributes, including:
Cost, Doctor recommendation, Manufacturing location, Similarity to the original product, Manufacturer, and
Safety record.
To test the impact basic biosimilar education has on patient beliefs and intentions, ISR split the sample into two
groups: one that received a brief definition of the difference between biologic and chemical medications and
one that did not receive the definition.
4. High-level Medication Perceptions
Reveals patients’ perceptions surrounding “simple” and “complex” medications. For example, ISR explores
patients’ perceptions of medication safety and effectiveness, attributes they associate with “complex”
medications, and the use and manufacturing of “simple” generic medications.
5. Perceptions of Biologic and Biosimilar Medications
Quantifies patients’ familiarity with and feelings towards biologic medicines.
6. Pharmaceutical Industry Perceptions
Measures patients’ trust of drug manufacturers by geographic location and reports pharmaceutical company-
level brand familiarity.
345US Respondents
144Charts and Graphs
97
Pages
•	 Identify product attributes that have the greatest impact on patients’
medication decisions
•	 Learn which patient segmentations are likely to need additional generics and
biosimilars education
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 3
act with confidence
Valuable for:
Respondent Demographics that mirror U.S. population:
# of drugs taken in past 6
months
Health insurance coverageAge
15%,
18-24
26%,
25-35
27%, 36-45
17%,
46-55
8%,
56-65
8%,
Over 65 years
39%,
4 or
more
61%,
1-3
48%
24%
14%
Employer
Medicare
Medicaid
•	 Marketing
•	 Brand Management
•	 Communications
•	 Public Relations
•	 Sales
•	 Training
•	 Advertising
What you will learn in this report:
•	 The general public’s knowledge and perceptions of biologic and biosimilar medications
•	 The effect basic biosimilar education has on perceptions and decision-making
•	 US population’s current beliefs about generic medicines and how those beliefs differ
for “generic” biologics
•	 Percentage of US population who know whether their own prescription medications
are chemical or biologic
How you can use this report:
•	 Establish your biosimilar commercialization strategy by leveraging this insight into
the US population’s knowledge, perceptions, and intentions for use of biologic and
biosimilar medicines
•	 Design biosimilar patient education campaigns rooted in the understanding of patients’
high-level drivers of choice
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 4
act with confidence
Table of Contents
Full table of contents and additional sample pages available in the full preview,
free on our website:
http://www.isrreports.com/product/public-knowledge-perceptions-and-in-
tentions-for-biologic-and-biosimilar-medicines/
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 5
act with confidence
act with confidence
Introduction
www.ISRreports.com ©2013 | Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 5
Introduction
Facts:
• Biologic medications are very expensive
• Blockbuster biologic drugs are coming off-patent over the next few years
• Biosimilars will not be offered in the United States for generic-like $4 per
prescription
• The consumer decision-making process regarding biosimilars will be vastly
more complicated than it is for chemical generics
Hypothesis:
US patients are relatively naive regarding the medications they take and their
understanding of biologic drugs is minimal� Knowledge can impact prescription
decision-making�
Impact:
If the hypothesis holds, this both affords an opportunity and presents a challenge
to setting strategies for pharmaceutical sales, marketing, and advertising�
The oncoming wave of biosimilar products in the United States will cause a
fundamental shift in the way US patients purchase medications� Successful
pharmaceutical sales, marketing, and brand management personnel need to
understand why consumers make the choices they do when it comes to these
“generic” medicines�
Why do some people take generic medications and others do not? Most people
in the United States can get their generic medications at a local Wal-Mart for
$4 per prescription, so it seems like a fairly easy economic decision� But there is
more to this decision than just economics� Maybe the pharmaceutical company
that made their original medication has a well-publicized co-pay card or they
offer a fairly inexpensive branded generic option or the consumer doesn’t trust
the generic manufacturer or their physician or family member has recommended
they stay on the original medication�
So while currently it might make economic sense for a consumer to switch
to a generic medication, what happens when the economic gap is not as
pronounced? ISR has learned through various research projects that the coming
biosimilars will not be offered for $4 per prescription� This research was designed
to provide pharmaceutical sales, marketing, and brand management with data to
help them understand how US patients will make what ISR believes to be a real
decision regarding their purchase and use of biosimilar medications�
Sample Page: Report Introduction
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 6
act with confidence
Sample Page
act with confidence
Medication decision-making
www.ISRreports.com ©2013 | Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 38
Respondents earning less than or equal to $45,000 income in 2012 (19%) are more
likely than respondents earning more than $45,000 income in 2012 (9%) to be
“extremely likely to switch to the less expensive, general alternative�”
Respondents whose main medication is a biologic product (53%) are more likely than
respondents who don’t know the composition of their main medication (22%) and
respondents whose main medication type is chemical (25%) to be “extremely likely to
stay on the more expensive, doctor-recommended drug�”
Total
(N=345)
<$45,000
(N=152)
F
>$45,000
(N=193)
G
Extremely likely to stay on
the more expensive, doctor-
recommended drug
29% 26% 32%
Somewhat likely to stay on
the more expensive, doctor-
recommended drug
37% 32% 40%
Somewhat likely to switch to the
less expensive, generic alternative
21% 23% 19%
Extremely likely to switch to the
less expensive, generic alternative
13% 19%
G
9%
Total
(N=345)
Biologic
(N=66)
J
Chemical
(N=148)
K
Don’t know
(N=131)
L
Extremely likely to stay on
the more expensive, doctor-
recommended drug
29% 53%
K, L
25% 22%
Somewhat likely to stay on
the more expensive, doctor-
recommended drug
37% 36% 36% 37%
Somewhat likely to switch to the
less expensive, generic alternative
21% 11% 24%
J
22%
J
Extremely likely to switch to the
less expensive, generic alternative
13% 0% 15%
J
18%
J
Income level
Main medication type
Willingness to switch to a generic against doctor’s orders:
Simple medication
Segment differences
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 7
act with confidence
Sample Page
Full table of contents and additional sample pages available in the full preview,
free on our website:
http://www.isrreports.com/product/public-knowledge-perceptions-and-in-
tentions-for-biologic-and-biosimilar-medicines/
www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 8
act with confidence
Ordering Information
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma
and pharma services industries.  With over a decade of experience in the industry, ISR delivers an un-
matched level of domain expertise. 
 
For more information about our off-the-shelf intelligence and custom research offerings, please visit
our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
About Industry Standard Research
For pricing and purchasing information, pleas visit our website:
http://www.isrreports.com/product/public-knowledge-perceptions-and-in-
tentions-for-biologic-and-biosimilar-medicines/

Contenu connexe

Plus de Industry Standard Research

Regulatory Affairs: Department Models and Structures
Regulatory Affairs: Department Models and StructuresRegulatory Affairs: Department Models and Structures
Regulatory Affairs: Department Models and StructuresIndustry Standard Research
 
CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)
CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)
CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)Industry Standard Research
 
Fill Finish Contract Manufacturer Quality Benchmarking (2016)
Fill Finish Contract Manufacturer Quality Benchmarking (2016)Fill Finish Contract Manufacturer Quality Benchmarking (2016)
Fill Finish Contract Manufacturer Quality Benchmarking (2016)Industry Standard Research
 
Market Access: department models and structures
Market Access: department  models and structuresMarket Access: department  models and structures
Market Access: department models and structuresIndustry Standard Research
 
Infographic: The World of Drug Development Trends
Infographic: The World of Drug Development TrendsInfographic: The World of Drug Development Trends
Infographic: The World of Drug Development TrendsIndustry Standard Research
 
Infographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and TechnologyInfographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and TechnologyIndustry Standard Research
 
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)Industry Standard Research
 
Infographic: Thyroid Cancer: Disease and Pipeline Analysis
Infographic: Thyroid Cancer:  Disease and Pipeline AnalysisInfographic: Thyroid Cancer:  Disease and Pipeline Analysis
Infographic: Thyroid Cancer: Disease and Pipeline AnalysisIndustry Standard Research
 
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsBenchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsIndustry Standard Research
 
Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...Industry Standard Research
 
Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug DevelopmentBrain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug DevelopmentIndustry Standard Research
 
What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?Industry Standard Research
 

Plus de Industry Standard Research (20)

Regulatory Affairs: Department Models and Structures
Regulatory Affairs: Department Models and StructuresRegulatory Affairs: Department Models and Structures
Regulatory Affairs: Department Models and Structures
 
CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)
CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)
CRO Quality Benchmarking – Phase IV Service Providers (8th EDITION)
 
Fill Finish Contract Manufacturer Quality Benchmarking (2016)
Fill Finish Contract Manufacturer Quality Benchmarking (2016)Fill Finish Contract Manufacturer Quality Benchmarking (2016)
Fill Finish Contract Manufacturer Quality Benchmarking (2016)
 
Market Access: department models and structures
Market Access: department  models and structuresMarket Access: department  models and structures
Market Access: department models and structures
 
Infographic: The World of Drug Development Trends
Infographic: The World of Drug Development TrendsInfographic: The World of Drug Development Trends
Infographic: The World of Drug Development Trends
 
Infographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and TechnologyInfographic: eClinical Trends, Tips, and Technology
Infographic: eClinical Trends, Tips, and Technology
 
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
EDC and eCOA/ePRO Market Dynamics and Service Provider Performance (2015)
 
Orphan Drug 101
Orphan Drug 101Orphan Drug 101
Orphan Drug 101
 
Infographic: Ovarian Cancer Profile
Infographic: Ovarian Cancer ProfileInfographic: Ovarian Cancer Profile
Infographic: Ovarian Cancer Profile
 
Infographic: CRO Capital Market
Infographic: CRO Capital MarketInfographic: CRO Capital Market
Infographic: CRO Capital Market
 
2014 Clinical Development Year in Review
2014 Clinical Development Year in Review2014 Clinical Development Year in Review
2014 Clinical Development Year in Review
 
Infographic: Thyroid Cancer: Disease and Pipeline Analysis
Infographic: Thyroid Cancer:  Disease and Pipeline AnalysisInfographic: Thyroid Cancer:  Disease and Pipeline Analysis
Infographic: Thyroid Cancer: Disease and Pipeline Analysis
 
Benchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs FunctionsBenchmarking the Pharma Industry’s Medical Affairs Functions
Benchmarking the Pharma Industry’s Medical Affairs Functions
 
Bladder Cancer: profile and drug development
Bladder Cancer: profile and drug developmentBladder Cancer: profile and drug development
Bladder Cancer: profile and drug development
 
Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...Clinical development activity in perspective: A head-to-head comparison of ...
Clinical development activity in perspective: A head-to-head comparison of ...
 
[Infographic] Lung Cancer
[Infographic] Lung Cancer[Infographic] Lung Cancer
[Infographic] Lung Cancer
 
Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug DevelopmentBrain Cancer (Glioblastoma Multiforme): Profile & Drug Development
Brain Cancer (Glioblastoma Multiforme): Profile & Drug Development
 
Clinical Development Year in Review (2013)
Clinical Development Year in Review (2013)  Clinical Development Year in Review (2013)
Clinical Development Year in Review (2013)
 
What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?What does the future hold for Detailing and drug reps?
What does the future hold for Detailing and drug reps?
 
The ISR Difference
The ISR DifferenceThe ISR Difference
The ISR Difference
 

Dernier

AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsEmily Kunka, MS, CCRP
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationKavitha Krishnan
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)MedicoseAcademics
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthGokuldas Hospital
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 

Dernier (20)

AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient Insights
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Forensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentationForensic Nursing powerpoint presentation
Forensic Nursing powerpoint presentation
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)
 
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint HealthArthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
Arthroscopic Surgery in Indore : A Minimally Invasive Guide to Joint Health
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 

Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines

  • 1. Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines Info@ISRreports.com ©2013 Industry Standard Research www.ISRreports.com PREVIEW
  • 2. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 2 act with confidence Report Overview T his research was designed to provide pharmaceutical sales, marketing, and brand management with data to better understand how US patients will make decisions regarding their purchase and use of biosimilar medications. Major Sections: 1. Executive Summary 2. Medication Decision-making Explores high-level prescribing activities and reveals patients’ predispositions when making prescription decisions. For example, ISR reveals patients’ likelihood to switch to a generic medication against doctor’s orders, how often they consult a pharmacist regarding drug decisions, and how often they request a generic alternative. 3. Biologic and Biosimilar Prescription Choice Models ISR analyzes the level of importance patients place on several prescription medication attributes, including: Cost, Doctor recommendation, Manufacturing location, Similarity to the original product, Manufacturer, and Safety record. To test the impact basic biosimilar education has on patient beliefs and intentions, ISR split the sample into two groups: one that received a brief definition of the difference between biologic and chemical medications and one that did not receive the definition. 4. High-level Medication Perceptions Reveals patients’ perceptions surrounding “simple” and “complex” medications. For example, ISR explores patients’ perceptions of medication safety and effectiveness, attributes they associate with “complex” medications, and the use and manufacturing of “simple” generic medications. 5. Perceptions of Biologic and Biosimilar Medications Quantifies patients’ familiarity with and feelings towards biologic medicines. 6. Pharmaceutical Industry Perceptions Measures patients’ trust of drug manufacturers by geographic location and reports pharmaceutical company- level brand familiarity. 345US Respondents 144Charts and Graphs 97 Pages • Identify product attributes that have the greatest impact on patients’ medication decisions • Learn which patient segmentations are likely to need additional generics and biosimilars education
  • 3. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 3 act with confidence Valuable for: Respondent Demographics that mirror U.S. population: # of drugs taken in past 6 months Health insurance coverageAge 15%, 18-24 26%, 25-35 27%, 36-45 17%, 46-55 8%, 56-65 8%, Over 65 years 39%, 4 or more 61%, 1-3 48% 24% 14% Employer Medicare Medicaid • Marketing • Brand Management • Communications • Public Relations • Sales • Training • Advertising What you will learn in this report: • The general public’s knowledge and perceptions of biologic and biosimilar medications • The effect basic biosimilar education has on perceptions and decision-making • US population’s current beliefs about generic medicines and how those beliefs differ for “generic” biologics • Percentage of US population who know whether their own prescription medications are chemical or biologic How you can use this report: • Establish your biosimilar commercialization strategy by leveraging this insight into the US population’s knowledge, perceptions, and intentions for use of biologic and biosimilar medicines • Design biosimilar patient education campaigns rooted in the understanding of patients’ high-level drivers of choice
  • 4. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 4 act with confidence Table of Contents Full table of contents and additional sample pages available in the full preview, free on our website: http://www.isrreports.com/product/public-knowledge-perceptions-and-in- tentions-for-biologic-and-biosimilar-medicines/
  • 5. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 5 act with confidence act with confidence Introduction www.ISRreports.com ©2013 | Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 5 Introduction Facts: • Biologic medications are very expensive • Blockbuster biologic drugs are coming off-patent over the next few years • Biosimilars will not be offered in the United States for generic-like $4 per prescription • The consumer decision-making process regarding biosimilars will be vastly more complicated than it is for chemical generics Hypothesis: US patients are relatively naive regarding the medications they take and their understanding of biologic drugs is minimal� Knowledge can impact prescription decision-making� Impact: If the hypothesis holds, this both affords an opportunity and presents a challenge to setting strategies for pharmaceutical sales, marketing, and advertising� The oncoming wave of biosimilar products in the United States will cause a fundamental shift in the way US patients purchase medications� Successful pharmaceutical sales, marketing, and brand management personnel need to understand why consumers make the choices they do when it comes to these “generic” medicines� Why do some people take generic medications and others do not? Most people in the United States can get their generic medications at a local Wal-Mart for $4 per prescription, so it seems like a fairly easy economic decision� But there is more to this decision than just economics� Maybe the pharmaceutical company that made their original medication has a well-publicized co-pay card or they offer a fairly inexpensive branded generic option or the consumer doesn’t trust the generic manufacturer or their physician or family member has recommended they stay on the original medication� So while currently it might make economic sense for a consumer to switch to a generic medication, what happens when the economic gap is not as pronounced? ISR has learned through various research projects that the coming biosimilars will not be offered for $4 per prescription� This research was designed to provide pharmaceutical sales, marketing, and brand management with data to help them understand how US patients will make what ISR believes to be a real decision regarding their purchase and use of biosimilar medications� Sample Page: Report Introduction
  • 6. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 6 act with confidence Sample Page act with confidence Medication decision-making www.ISRreports.com ©2013 | Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 38 Respondents earning less than or equal to $45,000 income in 2012 (19%) are more likely than respondents earning more than $45,000 income in 2012 (9%) to be “extremely likely to switch to the less expensive, general alternative�” Respondents whose main medication is a biologic product (53%) are more likely than respondents who don’t know the composition of their main medication (22%) and respondents whose main medication type is chemical (25%) to be “extremely likely to stay on the more expensive, doctor-recommended drug�” Total (N=345) <$45,000 (N=152) F >$45,000 (N=193) G Extremely likely to stay on the more expensive, doctor- recommended drug 29% 26% 32% Somewhat likely to stay on the more expensive, doctor- recommended drug 37% 32% 40% Somewhat likely to switch to the less expensive, generic alternative 21% 23% 19% Extremely likely to switch to the less expensive, generic alternative 13% 19% G 9% Total (N=345) Biologic (N=66) J Chemical (N=148) K Don’t know (N=131) L Extremely likely to stay on the more expensive, doctor- recommended drug 29% 53% K, L 25% 22% Somewhat likely to stay on the more expensive, doctor- recommended drug 37% 36% 36% 37% Somewhat likely to switch to the less expensive, generic alternative 21% 11% 24% J 22% J Extremely likely to switch to the less expensive, generic alternative 13% 0% 15% J 18% J Income level Main medication type Willingness to switch to a generic against doctor’s orders: Simple medication Segment differences
  • 7. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 7 act with confidence Sample Page Full table of contents and additional sample pages available in the full preview, free on our website: http://www.isrreports.com/product/public-knowledge-perceptions-and-in- tentions-for-biologic-and-biosimilar-medicines/
  • 8. www.ISRreports.com ©2013 | Preview of: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines 8 act with confidence Ordering Information Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services industries.  With over a decade of experience in the industry, ISR delivers an un- matched level of domain expertise.    For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports. About Industry Standard Research For pricing and purchasing information, pleas visit our website: http://www.isrreports.com/product/public-knowledge-perceptions-and-in- tentions-for-biologic-and-biosimilar-medicines/